Gossamer Bio Inc (NAS:GOSS)
$ 0.73 0 (0%) Market Cap: 165.14 Mil Enterprise Value: 132.56 Mil PE Ratio: 0 PB Ratio: 6.08 GF Score: 37/100

Gossamer Bio Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 14, 2020 / 07:40PM GMT
Release Date Price: $14.02 (+4.01%)
Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst

Okay. Welcome to the afternoon sessions of the BofA Virtual Vegas Health Care Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here at BofA. Also, I have Olivia Brayer with me on the line from my team, and we're really excited to have Gossamer presenting today. And speaking on behalf of Gossamer, we have a few folks. We have CEO, Sheila Gujrathi; we have Bryan Giraudo who's CFO; and we have Richard Aranda who is Senior VP of Clinical Development. And so welcome, guys.

Sheila, do you want to say anything just to kick it off? Then we get ready into some questions.

Sheila K. Gujrathi
Gossamer Bio, Inc. - Co-Founder, President, CEO & Director

Well, great. Thank you, Geoff and Olivia. Very excited to be at this virtual conference. It's been quite productive. So kudos to both of you and your teams for running such a successful conference. Really pleased to be here. Very excited to share updates we have for Gossamer despite the COVID-19 pandemic,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot